Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program

Background and Aim: Data on the clinical pharmacokinetics of cannabidiol (CBD) are scanty. We explored the effect of demographic and clinical variables on plasma concentrations of purified CBD in patients with Dravet (DS) and Lennox–Gastaut syndrome (LGS). Methods: The study design was an open, pros...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Pharmacol
Main Authors: Contin, Manuela, Mohamed, Susan, Santucci, Margherita, Lodi, Monica Anna Maria, Russo, Emilio, Mecarelli, Oriano, CBD LICE Italy Study Group
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2021
Teme:
Pharmacology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7966506/
https://ncbi.nlm.nih.gov/pubmed/33746760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.637801
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki